![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Astellas Pharma’s Transplant Drug Wins New FDA Approval
Astellas Pharma’s Transplant Drug Wins New FDA Approval
![AstellasPharma-Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/AstellasPharma-Logo.png?t=1626736932&width=430)
The FDA has approved Astellas Pharma’s Prograf (tacrolimus) for use in combination with other immunosuppressants to prevent organ rejection in lung transplant patients.
The approval was supported by real-world evidence of effectiveness as well as confirmatory clinical trials, the agency said.
Prograf, which is the first FDA-approved immunosuppressant for this treatment group, was previously cleared to prevent organ rejection in liver, kidney and heart transplant patients.
Upcoming Events
-
21Oct